Anergis SA (Lausanne, Switzerland) is a clinical-stage biopharmaceutical company discovering and developing breakthrough vaccines to treat allergies caused by airborne allergens. 

Allergy is the fastest growing chronic condition in the industrialized world.

Based on its proprietary Contiguous Overlapping Peptides (COP) technology, Anergis aims at offering patients a long-term cure from allergies and reduce the treatment time from currently 3-5 years to two months.

Its lead program, AllerT, for the treatment of birch pollen allergy has completed phase IIb clinical development.

For more information, please contact:

Sten Verland, PhD MSc

General Partner

Phone: +45 2422 1969